Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases

This review discusses emerging approaches to ocular drug delivery for retinal diseases. Intravitreal injections have proven to be an effective, safe, and commonly used drug delivery method. However, the optimal management of chronic retinal diseases requires frequent intravitreal injections over ext...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) Pa.), 2023-07, Vol.12 (4), p.402
Hauptverfasser: Ham, Yeji, Mehta, Hemal, Kang-Mieler, Jennifer, Mieler, William F., Chang, Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 402
container_title Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
container_volume 12
creator Ham, Yeji
Mehta, Hemal
Kang-Mieler, Jennifer
Mieler, William F.
Chang, Andrew
description This review discusses emerging approaches to ocular drug delivery for retinal diseases. Intravitreal injections have proven to be an effective, safe, and commonly used drug delivery method. However, the optimal management of chronic retinal diseases requires frequent intravitreal injections over extended periods of time. Although this can be achieved in a clinical trial environment, it is difficult to replicate in routine clinical practice. In addition, frequent treatment increases the risk of complications, incurs more costs, and increases the treatment burden for patients and caregivers. Given the aging global population and diabetes pandemic, there is an urgent need for drug delivery methods that support more durable retinal therapy while maintaining the efficacy and safety of currently available intravitreal therapies. Several innovative drug delivery methods are currently being investigated. These include sustained-release implants and depots using prodrugs, microparticles, and hydrogels, surgically implanted reservoirs, gene therapy via submacular injections or suprachoroidal injections, as well as topical and systemic therapies.
doi_str_mv 10.1097/APO.0000000000000623
format Article
fullrecord <record><control><sourceid>pubmed_wolte</sourceid><recordid>TN_cdi_pubmed_primary_37523432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37523432</sourcerecordid><originalsourceid>FETCH-LOGICAL-p683-4ce3127cfc5629d83df4e79493cd1c600b6863523d98ed70f43a6ce05d38c22f3</originalsourceid><addsrcrecordid>eNpNkF9rwjAUxcPYmOL8BmPkC9SluW3aPIruH7gpo-8lJjdrt2pLEhW__cp04IHLPQ8_DvceQu5jNomZzB6nq-WEXUpwuCJDHgseMZnL6ws_IGPvv_8gFjOe35IBZCmHBPiQrD7aPTZ07nZfdI5NvUd3pO8YqtZ4qraGTrvOtUpX6KltHQ0V0sKhChvcBtpa-omh3qo-ofaoPPo7cmNV43F83iNSPD8Vs9dosXx5m00XUSdyiBKNEPNMW50KLk0OxiaYyUSCNrEWjK1FLqA_0sgcTcZsAkpoZKmBXHNuYUQeTrHdbr1BU3au3ih3LP8_64HkBBzaJqDzP83ugK6sUDWhKlmcSplmEEl5LjDqRwL8Ah-yYNQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ham, Yeji ; Mehta, Hemal ; Kang-Mieler, Jennifer ; Mieler, William F. ; Chang, Andrew</creator><creatorcontrib>Ham, Yeji ; Mehta, Hemal ; Kang-Mieler, Jennifer ; Mieler, William F. ; Chang, Andrew</creatorcontrib><description>This review discusses emerging approaches to ocular drug delivery for retinal diseases. Intravitreal injections have proven to be an effective, safe, and commonly used drug delivery method. However, the optimal management of chronic retinal diseases requires frequent intravitreal injections over extended periods of time. Although this can be achieved in a clinical trial environment, it is difficult to replicate in routine clinical practice. In addition, frequent treatment increases the risk of complications, incurs more costs, and increases the treatment burden for patients and caregivers. Given the aging global population and diabetes pandemic, there is an urgent need for drug delivery methods that support more durable retinal therapy while maintaining the efficacy and safety of currently available intravitreal therapies. Several innovative drug delivery methods are currently being investigated. These include sustained-release implants and depots using prodrugs, microparticles, and hydrogels, surgically implanted reservoirs, gene therapy via submacular injections or suprachoroidal injections, as well as topical and systemic therapies.</description><identifier>ISSN: 2162-0989</identifier><identifier>EISSN: 2162-0989</identifier><identifier>DOI: 10.1097/APO.0000000000000623</identifier><identifier>PMID: 37523432</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Drug Delivery Systems ; Humans ; Intravitreal Injections ; Pharmaceutical Preparations ; Retina ; Retinal Diseases - drug therapy</subject><ispartof>Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2023-07, Vol.12 (4), p.402</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2023 Asia-Pacific Academy of Ophthalmology. Published by Wolters Kluwer Health, Inc. on behalf of the Asia-Pacific Academy of Ophthalmology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-7555-1585</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37523432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ham, Yeji</creatorcontrib><creatorcontrib>Mehta, Hemal</creatorcontrib><creatorcontrib>Kang-Mieler, Jennifer</creatorcontrib><creatorcontrib>Mieler, William F.</creatorcontrib><creatorcontrib>Chang, Andrew</creatorcontrib><title>Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases</title><title>Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)</title><addtitle>Asia Pac J Ophthalmol (Phila)</addtitle><description>This review discusses emerging approaches to ocular drug delivery for retinal diseases. Intravitreal injections have proven to be an effective, safe, and commonly used drug delivery method. However, the optimal management of chronic retinal diseases requires frequent intravitreal injections over extended periods of time. Although this can be achieved in a clinical trial environment, it is difficult to replicate in routine clinical practice. In addition, frequent treatment increases the risk of complications, incurs more costs, and increases the treatment burden for patients and caregivers. Given the aging global population and diabetes pandemic, there is an urgent need for drug delivery methods that support more durable retinal therapy while maintaining the efficacy and safety of currently available intravitreal therapies. Several innovative drug delivery methods are currently being investigated. These include sustained-release implants and depots using prodrugs, microparticles, and hydrogels, surgically implanted reservoirs, gene therapy via submacular injections or suprachoroidal injections, as well as topical and systemic therapies.</description><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Pharmaceutical Preparations</subject><subject>Retina</subject><subject>Retinal Diseases - drug therapy</subject><issn>2162-0989</issn><issn>2162-0989</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkF9rwjAUxcPYmOL8BmPkC9SluW3aPIruH7gpo-8lJjdrt2pLEhW__cp04IHLPQ8_DvceQu5jNomZzB6nq-WEXUpwuCJDHgseMZnL6ws_IGPvv_8gFjOe35IBZCmHBPiQrD7aPTZ07nZfdI5NvUd3pO8YqtZ4qraGTrvOtUpX6KltHQ0V0sKhChvcBtpa-omh3qo-ofaoPPo7cmNV43F83iNSPD8Vs9dosXx5m00XUSdyiBKNEPNMW50KLk0OxiaYyUSCNrEWjK1FLqA_0sgcTcZsAkpoZKmBXHNuYUQeTrHdbr1BU3au3ih3LP8_64HkBBzaJqDzP83ugK6sUDWhKlmcSplmEEl5LjDqRwL8Ah-yYNQ</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Ham, Yeji</creator><creator>Mehta, Hemal</creator><creator>Kang-Mieler, Jennifer</creator><creator>Mieler, William F.</creator><creator>Chang, Andrew</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><orcidid>https://orcid.org/0000-0001-7555-1585</orcidid></search><sort><creationdate>202307</creationdate><title>Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases</title><author>Ham, Yeji ; Mehta, Hemal ; Kang-Mieler, Jennifer ; Mieler, William F. ; Chang, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p683-4ce3127cfc5629d83df4e79493cd1c600b6863523d98ed70f43a6ce05d38c22f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Pharmaceutical Preparations</topic><topic>Retina</topic><topic>Retinal Diseases - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ham, Yeji</creatorcontrib><creatorcontrib>Mehta, Hemal</creatorcontrib><creatorcontrib>Kang-Mieler, Jennifer</creatorcontrib><creatorcontrib>Mieler, William F.</creatorcontrib><creatorcontrib>Chang, Andrew</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ham, Yeji</au><au>Mehta, Hemal</au><au>Kang-Mieler, Jennifer</au><au>Mieler, William F.</au><au>Chang, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases</atitle><jtitle>Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)</jtitle><addtitle>Asia Pac J Ophthalmol (Phila)</addtitle><date>2023-07</date><risdate>2023</risdate><volume>12</volume><issue>4</issue><spage>402</spage><pages>402-</pages><issn>2162-0989</issn><eissn>2162-0989</eissn><abstract>This review discusses emerging approaches to ocular drug delivery for retinal diseases. Intravitreal injections have proven to be an effective, safe, and commonly used drug delivery method. However, the optimal management of chronic retinal diseases requires frequent intravitreal injections over extended periods of time. Although this can be achieved in a clinical trial environment, it is difficult to replicate in routine clinical practice. In addition, frequent treatment increases the risk of complications, incurs more costs, and increases the treatment burden for patients and caregivers. Given the aging global population and diabetes pandemic, there is an urgent need for drug delivery methods that support more durable retinal therapy while maintaining the efficacy and safety of currently available intravitreal therapies. Several innovative drug delivery methods are currently being investigated. These include sustained-release implants and depots using prodrugs, microparticles, and hydrogels, surgically implanted reservoirs, gene therapy via submacular injections or suprachoroidal injections, as well as topical and systemic therapies.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>37523432</pmid><doi>10.1097/APO.0000000000000623</doi><orcidid>https://orcid.org/0000-0001-7555-1585</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2162-0989
ispartof Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2023-07, Vol.12 (4), p.402
issn 2162-0989
2162-0989
language eng
recordid cdi_pubmed_primary_37523432
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Drug Delivery Systems
Humans
Intravitreal Injections
Pharmaceutical Preparations
Retina
Retinal Diseases - drug therapy
title Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T23%3A47%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_wolte&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20Drug%20Delivery%20Methods%20and%20Approaches%20for%20the%20Treatment%20of%20Retinal%20Diseases&rft.jtitle=Asia-Pacific%20journal%20of%20ophthalmology%20(Philadelphia,%20Pa.)&rft.au=Ham,%20Yeji&rft.date=2023-07&rft.volume=12&rft.issue=4&rft.spage=402&rft.pages=402-&rft.issn=2162-0989&rft.eissn=2162-0989&rft_id=info:doi/10.1097/APO.0000000000000623&rft_dat=%3Cpubmed_wolte%3E37523432%3C/pubmed_wolte%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37523432&rfr_iscdi=true